248 related articles for article (PubMed ID: 29295694)
1. Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications.
Kalavska K; Conteduca V; De Giorgi U; Mego M
Curr Cancer Drug Targets; 2018; 18(10):967-978. PubMed ID: 29295694
[TBL] [Abstract][Full Text] [Related]
2. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
Schmidtova S; Kalavska K; Kucerova L
Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
[TBL] [Abstract][Full Text] [Related]
4. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
5. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.
Cavallo F; Feldman DR; Barchi M
Int J Dev Biol; 2013; 57(2-4):273-80. PubMed ID: 23784838
[TBL] [Abstract][Full Text] [Related]
6. Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples.
Lobo J; Constâncio V; Leite-Silva P; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
Clin Epigenetics; 2021 Apr; 13(1):70. PubMed ID: 33823933
[TBL] [Abstract][Full Text] [Related]
7. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: an overview.
Chieffi P; Chieffi S
J Cell Physiol; 2013 Aug; 228(8):1641-6. PubMed ID: 23359388
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics: a way to understand the origin and biology of testicular germ cell tumors.
Okamoto K
Int J Urol; 2012 Jun; 19(6):504-11. PubMed ID: 22375557
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
10. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.
Mendoza J; Martínez J; Hernández C; Pérez-Montiel D; Castro C; Fabián-Morales E; Santibáñez M; González-Barrios R; Díaz-Chávez J; Andonegui MA; Reynoso N; Oñate LF; Jiménez MA; Núñez M; Dyer R; Herrera LA
Br J Cancer; 2013 Jul; 109(1):68-75. PubMed ID: 23807173
[TBL] [Abstract][Full Text] [Related]
11. New Anti-Cancer Strategies in Testicular Germ Cell Tumors.
Chieffi P; De Martino M; Esposito F
Recent Pat Anticancer Drug Discov; 2019; 14(1):53-59. PubMed ID: 30636617
[TBL] [Abstract][Full Text] [Related]
12. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.
Oing C; Skowron MA; Bokemeyer C; Nettersheim D
Andrology; 2019 Jul; 7(4):487-497. PubMed ID: 30924611
[TBL] [Abstract][Full Text] [Related]
14. NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2.
Cardenas RP; Zyoud A; McIntyre A; Alberio R; Mongan NP; Allegrucci C
Stem Cell Res Ther; 2024 May; 15(1):128. PubMed ID: 38693576
[TBL] [Abstract][Full Text] [Related]
15. Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.
Piulats JM; Vidal A; García-Rodríguez FJ; Muñoz C; Nadal M; Moutinho C; Martínez-Iniesta M; Mora J; Figueras A; Guinó E; Padullés L; Aytés À; Molleví DG; Puertas S; Martínez-Fernández C; Castillo W; Juliachs M; Moreno V; Muñoz P; Stefanovic M; Pujana MA; Condom E; Esteller M; Germà JR; Capella G; Farré L; Morales A; Viñals F; García-Del-Muro X; Cerón J; Villanueva A
Clin Cancer Res; 2018 Aug; 24(15):3755-3766. PubMed ID: 29618620
[No Abstract] [Full Text] [Related]
16. Chromosomes and expression in human testicular germ-cell tumors: insight into their cell of origin and pathogenesis.
Looijenga LH; Gillis AJ; Stoop HJ; Hersmus R; Oosterhuis JW
Ann N Y Acad Sci; 2007 Dec; 1120():187-214. PubMed ID: 17911410
[TBL] [Abstract][Full Text] [Related]
17. Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin.
Korkola JE; Houldsworth J; Bosl GJ; Chaganti RS
BJU Int; 2009 Nov; 104(9 Pt B):1334-8. PubMed ID: 19840009
[TBL] [Abstract][Full Text] [Related]
18. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.
Romano FJ; Rossetti S; Conteduca V; Schepisi G; Cavaliere C; Di Franco R; La Mantia E; Castaldo L; Nocerino F; Ametrano G; Cappuccio F; Malzone G; Montanari M; Vanacore D; Quagliariello V; Piscitelli R; Pepe MF; Berretta M; D'Aniello C; Perdonà S; Muto P; Botti G; Ciliberto G; Veneziani BM; De Falco F; Maiolino P; Caraglia M; Montella M; De Giorgi U; Facchini G
Oncotarget; 2016 Dec; 7(51):85641-85649. PubMed ID: 27821802
[TBL] [Abstract][Full Text] [Related]
19. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.
Singh R; Fazal Z; Bikorimana E; Boyd RI; Yerby C; Tomlin M; Baldwin H; Shokry D; Corbet AK; Shahid K; Hattab A; Freemantle SJ; Spinella MJ
Mol Oncol; 2022 Feb; 16(3):683-698. PubMed ID: 34482638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
